Clinical Trial Update: A Study of AK129 in Patients With Advanced Malignant Tumors [Phase 1]

View source ↗

Summary

AK129 is being evaluated in a Phase 1 trial for patients with advanced malignant tumors and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• AK129 (anti-PD-1 and LAG-3 bispecific antibody)

Snippet

Sponsor: Akeso | Conditions: Advanced Malignant Tumors(Stage IA-IB) | Phase 1 | Status: RECRUITING